• Obtaining regulatory approval opens the door to bringing SoloSmart® to market in the European Union
Issoire (France), September 19, 2022, 7:30 a.m. CEST – BIOCORP (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacture of medical devices and injectable drug delivery systems, and SANOFI announce the finalization of the development of SoloSmart® during the opening of the annual congress of the EASD (European Association for the Study of Diabetes) in Stockholm, Sweden. SoloSmart® is compatible with SoloStar® and Doublestar® injection pens from the pharmaceutical group.
The result of the collaboration initiated in 2019 between the two companies is a device for Sanofi SoloStar®/ DoubleStar® insulin pens, which records information relating to the insulin dose, the time and date of each injection and the transmits via Bluetooth to a compatible mobile application. SoloSmart® automatically and accurately records injected doses, eliminating the need for the patient to keep a manual diary and possibly adapting to new uses of continuous glucose monitoring systems or connected BGMs.